Infectious Diseases: BioCryst's $69M HHS Contract for RAPIVAB
Tuesday, 1 October 2024, 03:42
BioCryst Pharmaceuticals has received a contract valued at up to $69 million from the US Department of Health and Human Services (HHS) for the procurement of RAPIVAB to treat influenza.
Contract Details
This contract represents a vital investment in the fight against infectious diseases, specifically targeting the increasingly concerning influenza outbreaks.
Impact on Treatment Availability
The acquisition of RAPIVAB under this contract will significantly enhance the treatment options available for patients suffering from influenza.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.